S100A12 is a novel molecular marker differentiating systemic-onset juvenile idiopathic arthritis from other causes of fever of unknown origin.

OBJECTIVE Fever of unknown origin (FUO) in children presents a diagnostic challenge. The differential diagnosis includes systemic-onset juvenile idiopathic arthritis (JIA), an autoinflammatory syndrome associated with activation of phagocytic cells that, at presentation, is difficult to differentiate from severe systemic infections. The aim of this study was to investigate whether serum concentrations of the phagocytic proinflammatory protein S100A12 may help in deciding whether to treat patients with FUO with antibiotics or immunosuppressive agents. METHODS Serum samples were obtained from 45 healthy control subjects and from 240 patients (60 with systemic-onset JIA, 17 with familial Mediterranean fever [FMF], 18 with neonatal-onset multisystem inflammatory disease [NOMID], 17 with Muckle-Wells syndrome [MWS], 40 with acute lymphoblastic leukemia [ALL], 5 with acute myeloblastic leukemia [AML], and 83 with systemic infections). All samples were collected at the time of presentation, before the initiation of any treatment, and concentrations of S100A12 were determined by enzyme-linked immunosorbent assay. RESULTS The mean +/- 95% confidence interval serum levels of S100A12 were as follows: in patients with JIA, 7,190 +/- 2,690 ng/ml; in patients with FMF, 6,720 +/- 4,960 ng/ml; in patients with NOMID, 720 +/- 450 ng/ml; in patients with MWS, 150 +/- 60 ng/ml; in patients with infections, 470 +/- 160 ng/ml; in patients with ALL, 130 +/- 80 ng/ml; in patients with AML, 45 +/- 60 ng/ml; in healthy control subjects, 50 +/- 10 ng/ml. The sensitivity and specificity of S100A12 to distinguish between systemic-onset JIA and infections were 66% and 94%, respectively. CONCLUSION S100A12, a marker of granulocyte activation, is highly overexpressed in patients with systemic-onset JIA or FMF, which may point to as-yet unknown common inflammatory mechanisms in these diseases. The measurement of S100A12 serum levels may provide a valuable diagnostic tool in the evaluation of FUO.

[1]  J. Sibilia,et al.  Interleukin-1 receptor antagonist (anakinra) treatment in patients with systemic-onset juvenile idiopathic arthritis or adult onset Still disease: preliminary experience in France , 2007, Annals of the rheumatic diseases.

[2]  V. Pascual,et al.  Blood leukocyte microarrays to diagnose systemic onset juvenile idiopathic arthritis and follow the response to IL-1 blockade , 2007, The Journal of experimental medicine.

[3]  D. Foell,et al.  Faecal S100A12 as a non-invasive marker distinguishing inflammatory bowel disease from irritable bowel syndrome , 2007, Gut.

[4]  D. Foell,et al.  Mechanisms of Disease: a 'DAMP' view of inflammatory arthritis , 2007, Nature Clinical Practice Rheumatology.

[5]  Paul Kellam,et al.  Specific gene expression profiles in systemic juvenile idiopathic arthritis. , 2007, Arthritis and rheumatism.

[6]  T. van der Poll,et al.  Neutrophil-derived S100A12 in acute lung injury and respiratory distress syndrome , 2007, Critical care medicine.

[7]  D. Foell,et al.  Effects of intra-articular corticosteroids and anti-TNF therapy on neutrophil activation in rheumatoid arthritis , 2007, Annals of the rheumatic diseases.

[8]  I. Lednev,et al.  Hexameric Calgranulin C (S100A12) Binds to the Receptor for Advanced Glycated End Products (RAGE) Using Symmetric Hydrophobic Target-binding Patches* , 2006, Journal of Biological Chemistry.

[9]  S. Holland,et al.  Neonatal-onset multisystem inflammatory disease responsive to interleukin-1beta inhibition. , 2006, The New England journal of medicine.

[10]  I. Touitou,et al.  A decision tree for genetic diagnosis of hereditary periodic fever in unselected patients , 2006, Annals of the rheumatic diseases.

[11]  F. Fusco,et al.  Fever of unknown origin: a systematic review of the literature for 1995–2004 , 2006, Nuclear medicine communications.

[12]  C. Dinarello,et al.  Rapid responses to anakinra in patients with refractory adult-onset Still's disease. , 2005, Arthritis and rheumatism.

[13]  V. Pascual,et al.  Role of interleukin-1 (IL-1) in the pathogenesis of systemic onset juvenile idiopathic arthritis and clinical response to IL-1 blockade , 2005, The Journal of experimental medicine.

[14]  C. Dinarello.  Blocking IL-1 in systemic inflammation , 2005, The Journal of experimental medicine.

[15]  D. Foell,et al.  Proinflammatory S100 proteins in arthritis and autoimmune disease. , 2004, Arthritis and rheumatism.

[16]  D. Foell,et al.  Early recruitment of phagocytes contributes to the vascular inflammation of giant cell arteritis , 2004, The Journal of pathology.

[17]  D. Foell,et al.  Monitoring neutrophil activation in juvenile rheumatoid arthritis by S100A12 serum concentrations. , 2004, Arthritis and rheumatism.

[18]  O Fitzgerald,et al.  Expression of the pro-inflammatory protein S100A12 (EN-RAGE) in rheumatoid and psoriatic arthritis. , 2003, Rheumatology.

[19]  D. Foell,et al.  Neutrophil derived human S100A12 (EN-RAGE) is strongly expressed during chronic active inflammatory bowel disease , 2003, Gut.

[20]  D. Foell,et al.  S100A12 (EN-RAGE) in monitoring Kawasaki disease , 2003, The Lancet.

[21]  J. Reveille,et al.  Guidelines for immunologic laboratory testing in the rheumatic diseases: an introduction. , 2002, Arthritis and rheumatism.

[22]  J. Drenth,et al.  Hereditary periodic fever. , 2001, The New England journal of medicine.

[23]  A. Schmidt,et al.  The multiligand receptor RAGE as a progression factor amplifying immune and inflammatory responses. , 2001, The Journal of clinical investigation.

[24]  Tony S. Tao,et al.  Proinflammatory properties of the human S100 protein S100A12 , 2001, Journal of leukocyte biology.

[25]  Y. Toyama,et al.  Macrophage- and neutrophil- dominant arthritis in human IL-1α transgenic mice , 2001 .

[26]  M. Hartmann,et al.  S100A12 Is Expressed Exclusively by Granulocytes and Acts Independently from MRP8 and MRP14* , 1999, The Journal of Biological Chemistry.

[27]  M. Neurath,et al.  RAGE Mediates a Novel Proinflammatory Axis A Central Cell Surface Receptor for S100/Calgranulin Polypeptides , 1999, Cell.

[28]  J. Jarvis,et al.  Pathogenesis and mechanisms of inflammation in the childhood rheumatic diseases. , 1998, Current opinion in rheumatology.

[29]  A. Stagg,et al.  Inflammatory cytokines and cytokine antagonists in whole blood cultures of patients with systemic juvenile chronic arthritis. , 1998, British journal of rheumatology.

[30]  R. Schneider,et al.  6 Systemic onset juvenile rheumatoid arthritis , 1998 .

[31]  A. Martini,et al.  Performance of the preliminary definition of improvement in juvenile chronic arthritis patients treated with methotrexate , 1998, Annals of the rheumatic diseases.

[32]  P. Arnow,et al.  Fever of unknown origin , 1997, The Lancet.

[33]  D. Felson,et al.  Preliminary definition of improvement in juvenile arthritis. , 1997, Arthritis and rheumatism.

[34]  P. Woo,et al.  Juvenile chronic arthritis , 1995, The Lancet.

[35]  R. Petersdorf,et al.  FEVER OF UNEXPLAINED ORIGIN: REPORT ON 100 CASES , 1961, Medicine.

[36]  Patricia Woo,et al.  Systemic juvenile idiopathic arthritis: diagnosis, management, and outcome , 2006, Nature Clinical Practice Rheumatology.

[37]  K. Fassbender,et al.  Still's disease in children and adults: A distinct pattern of acute-phase proteins , 2005, Clinical Rheumatology.

[38]  R. Petty,et al.  International League of Associations for Rheumatology: International League of Associations for Rheumatology classification of juvenile idiopathic arthritis: second revision, Edmonton, 2001 , 2004 .

[39]  Durack Dt,et al.  Fever of unknown origin--reexamined and redefined. , 1991 .